For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
NFL is neurofilament light chain protein, also known as Neurofilament light polypeptide, 68 kDa neurofilament protein, Neurofilament triplet L protein, NEFL, NF68, CMT1F, and CMT2E. It is a 68 kDa subunit of the three so-called neurofilament triplet proteins: light (68 kDa), medium (160 kDa) and heavy (200 kDa), which are major structural components of neurons. High levels of neurofilament have been observed during the progression of numerous neurological diseases. Many studies have demonstrated that NFL can be used as a biomarker for disease monitoring in Amyotrophic Lateral Sclerosis (ALS), multiple sclerosis (MS) and Huntington's disease. It has also been shown to act as a tumor suppressor and has been linked to carcinogenesis/metastasis of several malignancies including breast, prostate, lung, colon, and bladder cancer.
|Assay Target Class||Protein|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Central Nervous System|
|Unit Size||100 Assay Points|
Over these last few decades there has been a growing trend in drug discovery to use cellular systems and functional assays, in addition to biochemical assays, for the characterization of new potential therapeutics. The ability to study the interaction between a candidate drug and its target withi ...